NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$48.85 -0.32 (-0.65 %)
(As of 03/19/2019 04:00 PM ET)
Previous Close$49.17
Today's Range$48.76 - $49.87
52-Week Range$36.03 - $85.66
Volume148,700 shs
Average Volume212,283 shs
Market Capitalization$680.19 million
P/E Ratio23.37
Dividend YieldN/A
Beta1.73
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$213.31 million
Cash Flow$2.5038 per share
Book Value$10.78 per share

Profitability

Net Income$31.90 million

Miscellaneous

EmployeesN/A
Market Cap$680.19 million
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How will Eagle Pharmaceuticals' stock buyback program work?

Eagle Pharmaceuticals announced that its board has initiated a stock buyback program on Thursday, August 10th 2017, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 13.3% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) issued its quarterly earnings data on Thursday, February, 28th. The specialty pharmaceutical company reported $1.20 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.16 by $0.04. The specialty pharmaceutical company had revenue of $56.05 million for the quarter, compared to analysts' expectations of $54.17 million. Eagle Pharmaceuticals had a net margin of 14.96% and a return on equity of 17.76%. The firm's revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.05 EPS. View Eagle Pharmaceuticals' Earnings History.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Eagle Pharmaceuticals.

What price target have analysts set for EGRX?

4 equities research analysts have issued 12 month price targets for Eagle Pharmaceuticals' shares. Their forecasts range from $52.00 to $66.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $57.50 in the next twelve months. This suggests a possible upside of 17.7% from the stock's current price. View Analyst Price Targets for Eagle Pharmaceuticals.

What is the consensus analysts' recommendation for Eagle Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ". Post 4Q18, we are reiterating our Neutral rating and our 12- month price target on EGRX shares of $58. Pipeline setbacks in 2018 have created an overhang on the visibility of near term growth drivers for EGRX, which keeps us on the sidelines for now. Given the current visibility, we believe EGRX stock remains fairly valued at current levels. That said EGRX’s current business continues to perform well and the company is advancing Ryanodex for nerve agent exposure and acute radiation syndrome, both of which we believe have the potential to get into the strategic national stockpile, if successful." (2/28/2019)
  • 2. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (2/18/2019)

Has Eagle Pharmaceuticals been receiving favorable news coverage?

Press coverage about EGRX stock has trended somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eagle Pharmaceuticals earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Eagle Pharmaceuticals' key competitors?

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), NVIDIA (NVDA), Horizon Pharma (HZNP), Radius Health (RDUS) and Clovis Oncology (CLVS).

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:
  • Mr. Scott L. Tarriff, CEO & Director (Age 59)
  • Mr. David M. Pernock, Pres & Chief Operating Officer (Age 66)
  • Mr. Pete A. Meyers, Chief Financial Officer (Age 49)
  • Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 58)
  • Mr. Daniel O'Connor, Exec. VP of Biologics & Corp. Devel. (Age 39)

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.61%), Park West Asset Management LLC (7.04%), JW Asset Management LLC (2.85%), D. E. Shaw & Co. Inc. (1.91%), Millennium Management LLC (1.91%) and Norges Bank (1.82%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Scott Tarriff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Which major investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Rothschild & Co. Asset Management US Inc., FMR LLC, New York State Common Retirement Fund, JW Asset Management LLC, Bank of New York Mellon Corp, Northern Trust Corp and Canada Pension Plan Investment Board. View Insider Buying and Selling for Eagle Pharmaceuticals.

Which major investors are buying Eagle Pharmaceuticals stock?

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Millennium Management LLC, Norges Bank, WINTON GROUP Ltd, D. E. Shaw & Co. Inc., Two Sigma Investments LP, Citigroup Inc. and Chartwell Investment Partners LLC. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $48.85.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $680.19 million and generates $213.31 million in revenue each year. The specialty pharmaceutical company earns $31.90 million in net income (profit) each year or $2.09 on an earnings per share basis.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is http://www.eagleus.com.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  354 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  574
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: Derivative

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel